Disease-Free Survival
Figure 2 · Panel DFS
Panel DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Xin Wang, Ouying Yan, Jitao Zhou, Feng Wen, Yali Shen, Zhiping Li, Qiu Li, Wenling Wang, Xiaohong Cai, Shisheng Tan, Zi Wang, Qing Qiao, Dan Cao, Meng Qiu, Jiyan Liu, Hongfeng Gou, Ming Liu, Cheng Yi, Yu Yang, Qing Zhu, Deyun Luo, Yaqin Zhao, Ye Chen, Shang Wang, Qiaoli Wang, Ke Cheng, Min Ren, Xin Liu, Feng Xu, Feng Bi
JAMA Netw Open 9(6) e2616154
IMPORTANCE: Despite advances in D2 gastrectomy (ie, gastrectomy with D2 lymphadenectomy) and adjuvant chemotherapy, the value of adding postoperative radiotherapy (RT) to adjuvant chemotherapy after D2 gastrectomy remains a topic of ongoing debate. OBJECTIVE: To assess whether the addition of RT to the S-1 plus oxaliplatin (SOX) chemotherapy regimen increases disease-free survival (DFS) in patients with T4 or node-positive gastric cancer after D2 gastrectomy. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3 randomized clinical trial was conducted between December 1, 2012, and August 30, 2022, at 5 large tertiary hospitals in China. Eligible patients were aged 18 to 70 years with gastric adenocarcinoma who underwent R0 resection with D2 lymphadenectomy, had pathologic stage T4 or node-positive disease, and had no evidence of metastasis (M0). Intention-to-treat statistical analyses were conducted from January 14 to March 31, 2025. INTERVENTIONS: Participants were assigned 1:1 to receive concurrent chemoradiotherapy (SOX RT) or chemotherapy alone (SOX). The SOX RT group received 1 cycle of induction SOX, followed by RT (50.4 Gy in 28 fractions) with concurrent S-1 (50 mg twice daily), and then 3 cycles of SOX. The SOX group received 6 cycles of SOX (S-1 30-40 mg/m2 twice daily on days 1-14; oxaliplatin 130 mg/m2 on day 1, every 3 weeks). MAIN OUTCOMES AND MEASURES: The primary end point was 3-year DFS. Secondary end points included overall survival (OS) and adverse events. RESULTS: A total of 620 patients were randomly assigned to the SOX group (n = 311) or SOX RT group (n = 309). Patients had a median (IQR) age of 55 (47-62) years and included 401 males (64.7%). Overall, 274 patients (44.2%) had T4 disease, and 590 (95.2%) had node-positive disease. In the primary analysis for the prespecified 3-year DFS end point, there was no evidence of a between-group difference in DFS (SOX RT vs SOX: HR, 0.98; 95% CI, 0.73-1.33). Similarly, there was no evidence of a between-group difference in OS (HR, 0.86; 95% CI, 0.60-1.23). The Kaplan-Meier-estimated 3-year DFS rates were 70.5% in the SOX RT group and 69.3% in the SOX group (log-rank P = .93), and the corresponding 3-year OS rates were 80.8% and 78.4%, respectively (log-rank P = .41). At 5 years, the DFS rates were 60.0% and 57.3% (log-rank P = .76) and the corresponding OS rates were 73.7% and 71.4% (log-rank P = .55) in the SOX RT and SOX groups, respectively. Treatment-related adverse events were similar between groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with T4 or node-positive gastric cancer who underwent D2 gastrectomy, SOX RT did not significantly improve DFS or OS. Accordingly, among patients with D2-resected gastric cancer, the findings do not support routine addition of adjuvant chemoradiotherapy to chemotherapy. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR-TRC-12002919.
2 个 Figure · 2 个 KM 面板
Figure 2.. Kaplan-Meier Curves for Disease-Free Survival (DFS) in the Intention-to-Treat Population Patients were randomized to receive S-1 plus oxaliplatin (SOX; n = 311) or SOX plus radiotherapy (SOX RT; n = 309) after D2 gastrectomy. Tick marks indicate censored observations. The dashed vertical line indicates 36 months. P value was calculated using a 2-sided log-rank test.
Figure 2 · Panel DFS
Panel DFS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3.. Kaplan-Meier Curves for Overall Survival (OS) in the Intention-to-Treat Population Patients were randomized to receive S-1 plus oxaliplatin (SOX; n = 311) or SOX plus radiotherapy (SOX RT; n = 309) after D2 gastrectomy. Tick marks indicate censored observations. The dashed vertical line indicates 36 months. P value was calculated using a 2-sided log-rank test.
Figure 3 · Panel Overall_Survival_OS_
Panel Overall_Survival_OS_ 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。